Trial Profile
Evaluation of the Immunogenicity and Safety of Two Preparations of Trivalent Recombinant Baculovirus-Expressed Hemagglutinin Influenza Vaccine Administered Intramuscularly in Healthy Adults Ages 18-49 Years
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Influenza virus RIV3 vaccine-(FluBlok) (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors Protein Sciences Corporation
- 30 Oct 2007 New trial record.